DA32 Life Science Tech Acquisition Corp.

• US
• DA32 Life Science Tech Acquisition Corp.
• Finance

DALS

We are a newly organized blank check company incorporated in April 2021 as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. To date our efforts have been limited to organizational activities as well as activities related to this offering.

We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue an initial business combination target in any business industry or geographic region, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the biotechnology and life science infrastructure sector. 

In coming together as co-sponsors of DA32, Deerfield Management, ARCH Venture Partners and Section 32 aim to leverage their complementary capabilities and networks in order to acquire, merge with and grow a promising life science technology opportunity. Individually, each of our sponsors brings deep industry expertise and a broad network across the life science technology landscape, including both private and public companies in all stages of development. Collectively, we believe that our sponsors are well positioned to help DA32 successfully identify an attractive company and equip it with the tools and connections needed to accelerate growth and become a successful publicly traded company.

By combining the healthcare knowledge and sourcing networks of our sponsors, we intend to execute our strategy to bring forward a meaningful, positive impact on human health. With accelerating advancements in research technology and a boom in healthcare data and biological insights, we believe the time is ripe, and DA32 is strongly positioned to pursue opportunities in the life sciences technology industry. 
 

Offering Team

Pre-IPO Investors

Deal Highlights

less

More

Deal Tracker

Stock Price